Huchmed (HKG:0013) appointed Johnny Cheng, its executive director and chief financial officer, as acting chief executive officer, effective immediately, according to a Monday Hong Kong bourse filing.
Cheng assumes the role after CEO Weiguo Su took a medical leave, the filing said.
Su will remain chief scientific officer, with support from Hutchmed's scientific team, to continue its drug research and development programs.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.